Cyclic Amine Derivatives for Selective EP4 Receptor Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Prostaglandin E mediated diseases such as pain, glaucoma, ulcerative colitis, and osteoporosis lack effective therapeutic options that specifically target the EP4 receptor, which is involved in various pathological states including pain, inflammation, and bone disease.
Innovation Solution
Development of novel cyclic amine derivative compounds that act as selective agonists of the EP4 subtype of PGE2 receptors, providing analgesic, anti-inflammatory, antiglaucoma, and anti-osteoporosis activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Prostaglandin E mediated diseases are used, then general therapeutic options are available, but specific targeting of the EP4 receptor is lacking
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of prostaglandin E2 to create novel cyclic amine derivatives with formula (I). These structural modifications change the molecular parameters to achieve selective binding to the EP4 receptor while maintaining the desired therapeutic effects, thereby resolving the contradiction between general therapeutic availability and specific receptor targeting.
2Adaptability or versatility
If selective EP4 receptor agonists are developed, then targeted treatment of pain, inflammation, and bone disease is achieved, but lack of effective therapeutic options currently exists
Solution Approach 1:
The patent applies local quality by designing compounds with specific local structural features in formula (I) that target the EP4 receptor selectively. The molecular structure incorporates specific functional groups and spatial arrangements that interact with particular amino acid residues in the EP4 receptor binding site, enabling selective agonist activity while providing effective treatment for EP4-mediated diseases.
Data Source
AI summary
There is described a group of novel cyclic amine derivative compounds having an EP4 receptor agonistic activity. Specifically, the compounds according to the invention are provided with analgesic, antiinflammatory, antiglaucoma activity, and also with anti-osteoporosis and antiulcerative activity. The present invention therefore relates to novel cyclic amine derivative compounds, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as pain, glaucoma, ulcerative colitis and osteoporosis.